Personalized vaccine for first-line advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a personalized vaccine (Microlyvaq™) made just for your tumor, given together with standard chemo and immunotherapy (pembrolizumab). It is for people with advanced non-small cell lung cancer who have not yet started treatment for the advanced stage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (NSCLC) that has not been treated yet for advanced disease (stage IIIB, IIIC, or IV).
- You are 18 years old or older and can provide a recent tumor sample for testing.
- Your lung cancer does not have certain genetic changes (like EGFR, ALK, ROS1) that would require a different standard targeted therapy first.
- You have not had prior chemotherapy or immunotherapy for advanced lung cancer (prior treatment after surgery or radiation is okay if it was more than 6–12 months ago).
- You are willing to have blood tests and possibly a repeat biopsy during the study to help create a personalized vaccine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized mRNA vaccine (made from your own tumor's genetic fingerprint) combined with an immunotherapy drug called adebrelimab. The goal is to see if this combination can help prevent lung cancer from coming back or slow its growth.
This study tests a combination of a personalized vaccine made from your tumor's unique markers, a type of immunotherapy (PD-1 inhibitor), and radiation. The goal is to see if this mix can work better for advanced lung cancer that has progressed after initial treatment.
This trial tests giving radiation and immunotherapy together to people with advanced lung cancer that hasn't been treated yet. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial is testing a personalized approach to combining chemotherapy and immunotherapy for people with advanced non-small-cell lung cancer that doesn't have certain gene changes. The goal is to find the most effective treatment plan based on your immune system's response.
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
This trial tests a combination of a personalized vaccine (made from your tumor's unique markers), a drug that boosts your immune system (PD-1 inhibitor), and targeted radiation for people with advanced lung cancer that has progressed after initial treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Non-squamous Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.